Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 12/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.74 |
| ▸ | PRKACA | P17612 | 8/20 | 0.74 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | RORC | P51449 | 2/20 | 0.49 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.47 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12123094 | 0.88 | ROCK1 (0.76) | ROCK1CYP3A4PRKACAROCK2CYP2D6 | |
| SCHEMBL437336 | 0.87 | ROCK1 (0.60) | ROCK1CYP3A4PRKACAROCK2CYP2D6 | |
| SCHEMBL436463 | 0.87 | ROCK1 (0.74) | ROCK1CYP3A4PRKACAROCK2CYP2D6 | |
| SCHEMBL436436 | 0.85 | ROCK1 (1.00) | ROCK1CYP3A4PRKACAROCK2CYP2D6 | |
| SCHEMBL437294 | 0.83 | ROCK1 (1.00) | ROCK1CYP3A4PRKACAROCK2CYP2D6 | |
| SCHEMBL439252 | 0.81 | ROCK1 (0.75) | ROCK1CYP3A4PRKACAROCK2 | |
| SCHEMBL13213663 | 0.79 | ROCK1 (0.58) | ROCK1CYP3A4PRKACAROCK2CYP2D6 | |
| SCHEMBL12123149 | 0.78 | ROCK1 (0.62) | ROCK1CYP3A4PRKACAROCK2CYP2D6 | |
| SCHEMBL12123150 | 0.77 | ROCK1 (0.59) | ROCK1CYP3A4PRKACAROCK2CYP2D6 | |
| SCHEMBL12123119 | 0.77 | PSEN1 (0.71) | ROCK1CYP3A4PRKACAROCK2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278306-B2 | C-met protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278306-B2 | C-met protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120065213-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065213-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058271-B2 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058271-B2 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2032562-B1 | SELECTIVE INHIBITORS OF ROCK PROTEIN KINASE AND USES THEREOF | VERTEX PHARMA (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2007133622-A2 | SELECTIVE INHIBITORS OF ROCK PROTEIN KINASE AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270386-A1 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-20070270386-A1 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270386-A1 | Selective inhibitors of rock protein kinase and uses thereof | ROCK1, ROCK2, MYLK | ROCK1 1/4885CYP3A4 4395/4885PRKACA 99/4885 |
| US-20120065213-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, MYLK | ROCK1 4/4885CYP3A4 3859/4885PRKACA 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.